A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Weight

Interventions

DRUG

LIPO-102

LIPO-102 High dose

DRUG

LIPO-102 Low

LIPO-102 Low dose

DRUG

LIPO-102, Placebo

Placebo

Trial Locations (2)

San Diego

New York